65,437 trials
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants
Meningitis, Meningococcal
Primary: Percentage of Participants With at Least One Adverse Event (AE) — 91.7; 91.7; 91.7; 91.7 percentage of participants
Thrombosis
Primary: Total Number of Participants Who Completed the Study-Related Ultrasound (US) and Magnetic Resonance Imaging (MRI) With and Without Contrast — 133; 113; 113; 110…
Jaw, Edentulous
Primary: Change in Crestal Bone Level Between Surgery and 12 Months, to Compare Between the Titan Zircon Implant and the Titan Grade IV Implant. — 0.3; 0.1 mm — p=0.025
Dysthymic Disorder
Primary: Hamilton-Depression Rating Scale (HDRS-24 Items) — 10.88; 16.41 units on a scale — p=0.10
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85 — -0.020; 0.103; 0.108 Liters — p=< 0.001
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 78.6; 58.8; 100.0; 86.7 percentage of…
Squamous Cell Carcinoma
Primary: Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN. — 1.8 months
Adenocarcinoma of the Gastroesophageal Junction · Metastatic Gastric Cancer · Advanced Unresectable Gastric Cancer
Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012
Spinal Cord Injury · Urinary Tract Infection
Primary: Bladder Colonization — 62 percentage of participants
Preterm Birth · Low Birth Weight <2500 Grams · Verylow Birthweight <1500 Grams
Primary: Birthweight — 40; 26 participants
Locally Advanced or Metastatic Medullary Thyroid Cancer · Medullary Thyroid Cancer
Primary: Percentage of Time a Patient Experienced at Least 1 AE of CTCAE Grade >=2 in First 12 Months of Receiving Vandetanib in Patients Who Participated in Patient Outreach…
Sleep Apnea, Obstructive · Primary Open-angle Glaucoma
Primary: Relationship Between IOP Fluctuation Pattern With or Without CPAP Therapy in Patients With Moderate to Severe OSAS With or Without POAG — 44.4; 42.2 mVEq/h
Dementia
Primary: Completion of Training Intervention — 7 participants
Dysthymic Disorder
Primary: Hamilton Depression Rating Scale, 24 Items (HDRS) — 14.4; 13.3 units on a scale — p=<.05